Navigation Links
Interleukin Genetics Reports Third Quarter 2011 Financial Results
Date:11/10/2011

WALTHAM, Mass., Nov. 10, 2011 /PRNewswire/ -- Interleukin Genetics, Inc. (OTCQB: ILIU) today announced financial and operational results for the third quarter ended September 30, 2011.

Total revenue for the three months ended September 30, 2011 was $765,000, compared to $545,000 for the same period in the prior year. The increase was attributable to greater genetic test revenue.

Research and development expenses were $325,000 for the three months ended September 30, 2011, compared to $317,000 for the same period in the prior year. The Company continues its work in its weight management and periodontal disease programs.

Selling, general, and administrative expenses were $1.1 million for the three months ended September 30, 2011, compared to $1.2 million for the same period in the prior year. The decrease was primarily attributable to decreased corporate professional fees offset in part by increased patent-related legal fees and sales commissions paid to Amway.

The Company reported a net loss of $1.1 million, or $(0.03) per basic and diluted common share, for the third quarter of 2011, compared to a loss of $1.4 million, or $(0.04) per basic and diluted share, for the same period in the prior year. On September 30, 2011, the Company had cash and cash equivalents of $1.0 million and had $3.3 million available under its credit facility.

"We are pleased to show continued revenue growth for our Weight Management Genetic Test and Wellness Select combination products. Customers are now paying monthly or annual subscription fees to our premium weight management web-tools package," said Lewis H. Bender, Chief Executive Officer of Interleukin Genetics. "In addition, enrollment in our clinical study to demonstrate the utility of using our PST® genetic test to improve the management of patients at risk of periodontal disease with Renaissance Health and the University of Michigan is proceeding with approximately 3,300 patients of the desired 4,000 enrolled thus far."  

Conference Call and Webcast InformationInterleukin Genetics will host a live conference call and webcast today at 4:30 p.m. EST to review the Company's new business developments and second quarter financial results. To access the live call, dial 877-324-1976 (domestic) or 631-291-4550 (international). The live webcast and replay access will be available on the Investors section of the Company's Website at: www.ilgenetics.com.

About Interleukin Genetics, Inc. Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets a line of genetic tests under the Inherent Health® brand. The products empower individuals to prevent certain chronic conditions and manage their existing health and wellness through genetic-based insights with actionable guidance. Interleukin Genetics leverages its research, intellectual property and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. Interleukin Genetics' flagship products include its proprietary PST® genetic risk panel for periodontal disease and tooth loss susceptibility sold through dentists and the Inherent Health Weight Management Genetic Test that identifies the most effective diet and exercise program for an individual based on genetics. Interleukin Genetics is headquartered in Waltham, Mass. and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, please visit www.ilgenetics.com.

Certain statements contained herein are "forward-looking" statementsBecause such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those risks and uncertainties described in the Company's  annual report on Form 10-K for the year ended December 31, 2010 and other filings with the Securities and Exchange Commission. The Company disclaims any obligation or intention to update these forward-looking statements.Contacts:Interleukin Media:

Interleukin Investors:Jon Siegal / Kirsten Fallon

Eliot LurierSchwartz MSL

Interleukin Genetics, Inc.781-684-0770

781-398-0700interleukin@schwartzmsl.com

elurier@ilgenetics.com INTERLEUKIN GENETICS, INC.FINANCIAL HIGHLIGHTSBalance Sheet Data : (Unaudited)September 30,December 31,20112010(Unaudited)Cash and cash equivalents

$
,014,764$
3,999,029Total current assets

$
,438,829$
4,752,790Total assets$
2,368,749$
5,975,000Total current liabilities

$
2,424,111$
,633,096Total liabilities$
2,424,111$
2,633,096Total shareholders' deficit

$
(10,055,362)$
(6,658,096)Total liabilities and shareholders' deficit

$
2,368,749$
5,975,000Statement of Operations Data (Unaudited): Three Months Ended Sept. 30,Nine Months Ended Sept. 30,2011201020112010Revenue:Genetic testing service revenue

$
731,194$
531,151$
2,229,757$
,460,601Other34,22213,59352,00825,805Total revenue765,416544,7442,281,7651,486,406Cost of revenue

370,740409,0101,166,7931,254,033Gross profit (loss)

394,676135,7341,114,972232,373Operating costs and expenses:Research and development

324,669317,155989,2871,059,450Selling, general and administrative

1,086,6061,168,3143,542,2034,209,879Amortization of intangibles

28,86328,86386,59086,590Total operating expenses

1,440,1381,514,3324,618,0805,355,919Loss from operations

(1,045,462)(1,378,598)(3,503,108)(5,123,546)Total other income and (expense), net

(89,080)(63,545)(257,778)(177,371)Loss from continuing operationsbefore income taxes

(1,134,542)(1,442,143)(3,760,886)(5,300,917)Income taxes----Loss from continuing operations

$
(1,134,542)$
(1,442,143)$
(3,760,886)$
(5,300,917)Income from discontinued operations,net of  income taxes

-158,366482,530Net loss$
(1,134,542)$
(1,442,143)$
(3,602,520)$
(4,818,387)Basic and diluted net (loss) income per common share from:Continuing operations

$
(0.03)$
(0.04)$
(0.10)$
(0.15)Discontinued operations

0.000.000.000.01Net loss$
(0.03)$
(0.04)$
(0.10)$
(0.14)Weighted average common shares outstanding,basic and diluted

36,674,82936,545,74736,647,87435,410,705
'/>"/>

SOURCE Interleukin Genetics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Interleukin Genetics, Inc. Announces Conference Call to Discuss Third Quarter 2011 Results
2. Interleukin Genetics, Inc. to Present at the 2011 Wedbush Securities Life Sciences Management Access Conference
3. Interleukin Genetics, Inc. Announces Conference Call to Discuss Second Quarter 2011 Results
4. Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise in the Treatment of Active Rheumatoid Arthritis
5. Interleukin Genetics Reports Fourth Quarter and Year End 2010 Financial Results
6. Interleukin Genetics, Inc. to Present at Biotech Showcase 2011
7. Interleukin Genetics, Inc. Receives Delisting Notification from NYSE Amex
8. Interleukin Genetics to Present at Upcoming Biotech Industry Meetings
9. Interleukin Genetics to Present at the 12th Annual BIO CEO Conference
10. Continued Uptake of TNF-Alpha Inhibitors and Interleukin Inhibitors Will Drive $2.2 Billion Growth in the Psoriasis Drug Market
11. Interleukin Genetics Reports Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) is ... treatments and faster cures for prostate cancer. Members of the Class of 2016 ... countries. Read More About the Class of 2016 PCF ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, ... of the Supplyframe Design Lab . Located in Pasadena, Calif., the Design ... of how hardware projects are designed, built and brought to market. , The ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
(Date:6/23/2016)... On Wednesday, June 22, 2016, the NASDAQ Composite ... Jones Industrial Average edged 0.27% lower to finish at 17,780.83; ... has initiated coverage on the following equities: Infinity Pharmaceuticals Inc. ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ), ... more about these stocks by accessing their free trade alerts ...
Breaking Biology Technology:
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... of Infosys (NYSE: INFY ), and Samsung SDS, ... partnership that will provide end customers with a more ... payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) ... financial services, but it also plays a fundamental part in ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys ... founding CEO, Barrett Bready , M.D., who returned ... of the original technical leadership team, including Chief Technology ... of Product Development, Steve Nurnberg and Vice President of ... to the company. Dr. Bready served as ...
Breaking Biology News(10 mins):